FertilitySA
Adelaide, South Australia, 5006, Australia
NCT Number: NCT02305420
EmbryoGen and BlastGen contain the cytokine growth factor Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), which has been documented to give significant benefit to this difficult group of patients.
Results showed a highly significant effect of 44% relative improvement in ongoing implantation rate (p=0.001) in women who have previously miscarried (Ziebe et al 2013).
We wish to undertake a randomised Controlled trial to determine if EmbryoGen/BlastGen media improves pregnancy outcomes in women with recurrent implantation failure, recurrent miscarriage and poor embryo development when compared to standard media.
Looking for future studies?
Notify Me25 year–41 year
Female
Interventional
Phase 4
Adelaide, South Australia, 5006, Australia
A randomised control pilot study will be undertaken for 100 women who have implantation failure (≥ 2 embryo transfers without a pregnancy) or at least 1 previous miscarriage and are having a further IVF cycle.
At oocyte retrieval each couple will be randomised using numbered envelopes containing pre randomised group allocations by a person uninvolved in the trial to:
The best single embryo will be transferred on day 5.
The clinical staff and participating couple will be blinded as to whether BlastGen or standard media was used in culture to day 5. Fertility SA embryologists will not be blind as to which study group a couple is in and which media is being used. The embryos will be cultured using the usual methods and lab facilities by Fertility SA's current embryology staff members who will not be blind to the media being used.
Records on the outcome of the oocyte fertilisation, blastocyst development, implantation rate and pregnancy rates will be recorded, as is standard practice. Pregnancy scans will be carried out at 7 and 12 weeks. Live birth outcomes and any congenital anomalies will be recorded.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
Other names: GM-CSF containing media
Standard Cook IVF media will be used in the control arm
Time frame: 9 months after closure of trial (18 +9 months)
Any delivery >20 resulting in a livebirth
Time frame: 9 months after closure of trial (18 +9 months)
number of liveborns with a congenital anomaly
Time frame: 18 months
Fetal Heart Beat seen on Ultrasound scan at 7 and 12 weeks
Time frame: 18 months
Number of blastocysts per cycle
Time frame: 18 months
grade of day 3 and day 5 embryos
Time frame: 18 months
Number of Frozen blastocysts
FertilitySA
Industry
Acronym: BlastGen
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05169541
Abortion, Habitual, Abortion, Spontaneous
Aarhus, Denmark
View Trial DetailsNCT03970954
Abortion, Habitual, Abortion, Spontaneous
Paris, Hopital Saint Antoine, France
View Trial DetailsNCT05216068
Abortion, Habitual, Abortion, Spontaneous
Kaohsiung City, Taiwan
View Trial DetailsNCT06001060
Abortion, Habitual, Abortion, Spontaneous
Hangzhou, China
View Trial Details